All doses to be taken will be 'printed' in a single capsule

We live in an age where health care is becoming more personalized, as the healing process can be tailored to different individuals.

According to Digital Trends, a new drug will allow pharmacists to create patients' dosages based on their own needs extremely quickly and easily. This means that instead of having to remember to take three pills, the other two, and so on, they will be able to get all the needed pills in a much simpler way.

Picture 1 of All doses to be taken will be 'printed' in a single capsule
AutoCompounder is capable of printing complex multipurpose tablets.

The size of this baking-sized 3D printer is called AutoCompounder , created by a startup called Vitae Industries . It has the ability to print 3D pills and candies that only take about a third of the time compared to a pharmacist stuffing drugs into the capsule manually. AutoCompounder even has the ability to print complex multipurpose tablets, which incorporate multiple doses into a single tablet.

"AutoCompounder helps pharmacists create more effective doses of oral medications." The standard dosage sold on the market for many prescription drugs is often not suitable for many people. Providing individualized dosages for individuals will help transform the pharmaceutical industry and enhance the health of everyone through individual healing rather than general cure, " said CEO Vitae Jeanine Sinanan-Singh. .

This is a great idea and ambitious. If Vitae Industries succeeds, it will bring many advantages to many patients. The machine only takes 10 minutes to create a tablet of your choice, and does not require much more than the pharmacist to control the drug and the dose needed. After completing the preparation of the tablet, the machine will automatically clean itself so as not to cause cross infection.

The machine, which costs $ 5,000, is not yet sold, Vitae also refused to share any images of it. This startup has earned more than $ 2 million in private equity. According to CEO of Vitae Industries, the first limited test program will begin in the first quarter of 2018 for selected pre-selected pharmacies.